MorphoSys Finds Right Time To Focus On Pipeline With AbD Serotec Sale To Bio-Rad Labs

MorphoSys sells some of its assets in an effort to concentrate on its proprietary therapeutic endeavors – including a mid-stage rheumatoid arthritis drug.